TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Travere Therapeutics, Inc.
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$50.49+0.89 (+1.79%)
Close on Oct 19, 2026
- Market cap
- $4.72B
- P/E (TTM)
- –
- Dividend yield
- –
Travere Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net product sales | $410.46M | $226.71M | $127.54M | $97.97M | $115.12M | $198.32M | $175.34M | – | – | – | 83.6% | +81.1% |
| FILSPARI | $322.01M | $132.22M | $29.21M | $0 | $0 | – | – | – | – | – | 65.6% | +143.5% |
| Tiopronin products | $88.46M | $94.49M | $98.33M | $97.97M | $115.12M | $108.88M | $95.64M | $89.18M | – | – | 18.0% | -6.4% |
| License and collaboration revenue | $80.27M | $6.47M | $17.70M | $11.49M | $16.71M | $0 | $0 | – | – | – | 16.4% | +1141.0% |
| Bile acid products | – | – | – | $102.56M | $95.65M | $89.44M | $79.70M | $75.07M | $72.63M | $62.39M | – | – |
| Thiola License | – | – | – | – | – | – | $95.64M | $89.18M | $82.31M | $71.20M | – | – |
| Clinical Development Activity | – | – | $14.40M | – | – | – | – | – | – | – | – | – |
| Active Pharmaceutical Ingredient | – | – | $3.30M | – | – | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Travere Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.